Between 2022 and 2025, voluntary attrition among software engineers and digital product professionals at the top 20 US pharmaceutical companies averaged 31% annually — nearly double the 17% rate observed across the pharma workforce as a whole. The departures were concentrated at the most senior levels: Directors and VPs of Engineering, Heads of Data Science, and digital product leaders who had been recruited from technology companies with significant compensation premiums and transformation mandates. The pattern was consistent across Pfizer, Johnson & Johnson, Roche, Novartis, Merck, AstraZeneca, and virtually every major pharma company that invested in digital transformation teams between 2019 and 2023.
This attrition represents one of the most significant talent challenges facing the pharmaceutical industry. Pharma companies have collectively invested billions of dollars in digital transformation initiatives — building data platforms, deploying AI in R&D, modernizing supply chain systems, and creating patient-facing digital therapeutics — and the talent they recruited to lead those initiatives is leaving faster than it can be replaced. Understanding why requires examining the specific friction points that make pharma an exceptionally difficult environment for technology professionals, and what the companies that retain digital talent best are doing differently.
Why digital talent actually leaves pharma
From our conversations with over 80 senior technology professionals who left pharmaceutical companies between 2023 and 2025, the reasons clustered into four categories, and they are more specific than the generic “culture mismatch” narrative that industry commentary typically offers.
Decision velocity. The single most cited frustration: the time required to move from concept to deployment in pharma is 3x to 5x longer than what technology professionals experienced in their prior environments. A software deployment that would take 2–4 weeks at a technology company routinely takes 3–6 months at a pharma company after validation protocols, compliance reviews, change control processes, and cross-functional alignment meetings. Many of these processes exist for legitimate regulatory reasons — GxP-compliant systems genuinely require more rigorous validation than consumer software — but the cumulative effect on engineering morale is pronounced. Senior engineers who joined pharma excited about transforming drug discovery or supply chain operations find themselves spending 60–70% of their time in documentation and approval processes rather than building.
Technical debt and legacy infrastructure. Most large pharma companies operate on technology stacks that are 15–25 years old. Core systems — LIMS, ERP, clinical data management, regulatory submission platforms — were built on architectures that predate cloud computing, modern APIs, and containerized deployment. The engineers recruited to “transform” these systems quickly discover that transformation means years of incremental migration rather than greenfield development, and that the political resistance to replacing systems that “work” (however inefficiently) is formidable.
Organizational positioning. At most pharma companies, the technology function reports into a shared-services or IT organization that is structurally subordinate to the scientific and commercial functions. Engineers and data scientists who were accustomed to being core value creators at technology companies find themselves positioned as support functions in pharma — asked to build tools for scientists rather than co-creating scientific strategy. This positioning affects not just morale but career trajectory: the path from VP of Engineering to the C-suite is well-established at technology companies and essentially nonexistent at most pharma companies.
The legacy systems problem in detail
The technical infrastructure challenge at large pharma companies deserves specific examination because it is the factor most commonly underestimated by technology professionals evaluating pharma opportunities. A typical top-20 pharma company operates between 800 and 2,500 distinct software applications, of which 40–60% are classified as “legacy” (end-of-life vendor support, outdated architecture, limited API capability). The integration complexity among these systems — many of which handle regulated data subject to 21 CFR Part 11 requirements — means that replacing any single system requires mapping and validating data flows across dozens of interconnected platforms.
For an engineer accustomed to the modern data stack at a technology company — cloud-native infrastructure, microservices architecture, CI/CD pipelines, and rapid iteration — the pharma legacy environment can feel like working in a different decade. The frustration is not that the systems are old; it is that the regulatory and organizational constraints make modernization extraordinarily slow. A cloud migration that would take 6 months at a technology company can take 3–4 years at a pharma company when computer system validation (CSV) requirements, data integrity protocols, and regulatory submission dependencies are factored in.
The compensation gap
Compensation is the most quantifiable friction point. In our 2025 data, the total compensation gap between pharma and pure technology companies for equivalent senior engineering roles was 35–55%, driven primarily by equity:
VP of Engineering: Pharma $340K–$480K total comp versus Big Tech $580K–$950K total comp. The cash compensation gap is smaller (pharma base salaries are 10–20% below tech equivalents), but the equity gap is dramatic: pharma RSU grants for VP-level engineering are typically $80K–$150K annually, versus $200K–$500K at major tech companies.
Director of Data Science: Pharma $260K–$380K total comp versus Big Tech $420K–$680K total comp. Again, the gap is primarily in equity, though pharma bonus structures (typically 20–30% of base) partially offset the difference.
Senior ML Engineer: Pharma $195K–$280K total comp versus Big Tech $320K–$520K total comp. At this level, the gap is large enough that many candidates do not seriously consider pharma opportunities regardless of mission alignment.
Regulatory friction and engineering culture
The tension between pharmaceutical regulation and engineering culture is structural, not cultural. GxP requirements — Good Manufacturing Practice, Good Clinical Practice, Good Laboratory Practice — impose specific validation, documentation, and change-control requirements on any system that touches regulated data. These requirements exist because pharmaceutical errors can kill patients, and the regulatory framework that enforces them is not going to change to accommodate engineering preferences for rapid iteration.
The pharma companies that navigate this tension most effectively do not try to make regulatory compliance feel like working at a tech company. Instead, they invest in compliance automation — tools and platforms that automate computer system validation, generate documentation from code, and embed regulatory requirements into the CI/CD pipeline rather than adding them as manual steps after development. Companies like Veeva Systems, which built a cloud platform specifically designed for pharma’s regulatory requirements, have demonstrated that GxP compliance and modern software engineering practices are not inherently incompatible — they simply require purpose-built tooling that most pharma companies have not yet invested in.
Strategies that attract and retain tech talent in pharma
The pharma companies with the lowest technology talent attrition share five specific characteristics:
- Dedicated technology organizations. Companies that have created distinct technology units with their own leadership, culture, and operating model — rather than embedding engineers in the traditional IT function — report 40–50% lower attrition among senior technology hires. Roche’s creation of a separate digital organization and Novartis’s Microsoft partnership are examples of this approach.
- Competitive equity. Companies that offer equity packages within 20% of tech-sector equivalents, rather than applying standard pharma equity scales, retain senior engineers at materially higher rates. Some pharma companies have created “tech talent bands” that sit outside their standard compensation framework specifically to address this gap.
- Modern tooling mandates. Pharma companies that have invested in cloud-native development platforms, automated validation tools, and modern data infrastructure give their engineering teams an environment that is closer to what they experienced at technology companies. The investment is significant — typically $50M–$150M for a top-20 pharma company — but the retention impact is measurable.
- Clear technical career ladders. Pharma companies that have established individual-contributor technical career paths (analogous to the Staff/Principal/Distinguished Engineer ladder at tech companies) retain senior engineers who would otherwise leave because the only advancement path requires moving into management.
- Mission-oriented project assignment. Engineers who are assigned to projects with visible patient impact — clinical trial platforms, diagnostic algorithms, patient-facing digital therapeutics — show 25% higher retention than those assigned to internal infrastructure or operational efficiency projects.
The path forward
The pharma industry’s digital talent challenge is not temporary. The demand for software engineers, data scientists, ML engineers, and digital product leaders in pharma will continue to grow as AI-driven drug discovery, digital clinical trials, and real-world evidence platforms become standard rather than experimental. The companies that solve the retention problem will build a durable competitive advantage; the companies that continue to cycle through technology hires every 18–24 months will spend more on recruiting than on the transformation work itself.
For software engineers and digital leaders considering pharma opportunities, the diligence question is specific: has this company created the organizational and technical conditions for technology professionals to succeed, or is it recruiting technology talent into an environment that has not changed to accommodate them? The answer is visible in the company’s technology leadership tenure data, its infrastructure investment history, and the reporting structure of its engineering function. Ask for all three before accepting an offer. For current compensation context across life sciences leadership, see our 2026 Life Sciences Compensation Report.